Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.
Fountzilas E, Kotoula V, Tikas I, Manousou K, Papadopoulou K, Poulios C, Karavasilis V, Efstratiou I, Pectasides D, Papaparaskeva K, Varthalitis I, Christodoulou C, Papatsibas G, Chrisafi S, Glantzounis GK, Psyrri A, Aravantinos G, Koliou GA, Koukoulis GK, Pentheroudakis GE, Fountzilas G. Fountzilas E, et al. Among authors: fountzilas g. Oncotarget. 2018 Nov 2;9(86):35623-35638. doi: 10.18632/oncotarget.26256. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479693 Free PMC article.
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Fountzilas G, et al. Clin Breast Cancer. 2003 Jun;4(2):120-5. doi: 10.3816/cbc.2003.n.017. Clin Breast Cancer. 2003. PMID: 12864940
Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study.
Bamias A, Syrigos K, Fountzilas G, Tzamakou E, Soulti K, Karavasilis V, Alamanos Y, Christodoulou C, Pavlidis N. Bamias A, et al. Among authors: fountzilas g. Am J Clin Oncol. 2004 Oct;27(5):465-71. doi: 10.1097/01.coc.0000128870.72525.c7. Am J Clin Oncol. 2004. PMID: 15596912 Clinical Trial.
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer.
Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G; Hellenic Cooperative Oncology Group. Makatsoris T, et al. Among authors: fountzilas g. Int J Gastrointest Cancer. 2005;35(2):103-9. doi: 10.1385/ijgc:35:2:103. Int J Gastrointest Cancer. 2005. PMID: 15879624 Clinical Trial.
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G, Aravantinos G. Skarlos DV, et al. Among authors: fountzilas g. Anticancer Res. 2005 Jul-Aug;25(4):3103-8. Anticancer Res. 2005. PMID: 16080573 Free article. Clinical Trial.
Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).
Timotheadou E, Papakostas P, Tsavdaridis D, Basdanis G, Kalofonos H, Aravantinos G, Bafaloukos D, Fountzilas G. Timotheadou E, et al. Among authors: fountzilas g. Tumori. 2005 Jul-Aug;91(4):309-13. doi: 10.1177/030089160509100404. Tumori. 2005. PMID: 16277094 Clinical Trial.
600 results